We are a vertically integrated pharmaceutical company committed to delivering
high-quality healthcare for patients around the world.
Accelerating access to quality medicines
We work to identify new and existing gaps, and strengthen healthcare and life science by addressing them.
Addressing unmet and evolving patient needs
We are enhancing our capacities to develop high-quality, differentiated solutions to ensure good health and well-being for people everywhere.
Creating benchmarks in innovation
We believe that our strengths lie in leveraging them appropriately to deliver long-term, sustainable value to our customers and shareholders.
Delivering sustained returns
Working with an unflinching sense of duty towards the communities where our operations thrive and the planet at large.
Touching lives in myriad ways
Seeking innovative minds who aspire to broaden the horizons of quality healthcare and connecting them with growth opportunities are our top priorities as responsible employers.
Developing path-breaking solutions
Our latest press releases and announcements.
Setting the trend
Our enriching suite of products cater to our partners across the world, providing a diverse range that enables quality treatment for millions. We aspire to continuously grow this business through geographic expansions as well as partnerships and alliances made through joint ventures and subsidiaries across global markets. We have a well-established US front-end that is strengthened by strong customer bonds and a robust supply chain. We benefit from long-standing relationships with our partners across Europe, Canada, Australia, Brazil and South Africa.
Products under International Generics are manufactured across our world-class facilities in Panelav, Karkhadi and Jarod in Gujarat. Under this vertical, we also have dedicated R&D facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (USA).
We are among the largest generic pharmaceutical companies in India. Our objective is to deliver affordable, quality medicines, recommended by healthcare professionals and patients worldwide.
Our strength lies in developing generic and complex products with a robust pipeline of ANDAs, including high value categories. We seek out value-accretive, long-term partnerships, as key enablers of our growth strategy.
The success of our collaborations as well as integrated, organisational and commercial capabilities find expression in a track record of successful product launches.
Abbreviated New Drug Applications (ANDA) FY 2022-23
ANDA filings in 2022-23
(Includes 24 tentative
To know more on our therapies in International Generics, visit Alembic US website